Calidi Biotherapeutics Inc
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Calidi Biotherapeutics' stock with a target price of $20.
Financial Health
Calidi Biotherapeutics is showing strong cash flow and has a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CLDI
Cancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Matter
Progress in trials or regulatory steps can change sentiment quickly, though outcomes are uncertain and setbacks are common.
Capital & Dilution Watch
Small biotech firms often need additional funding; watch cash runway and financing plans as these can dilute existing shareholders.
Follow Official Updates
Company filings and press releases provide the most reliable information, but remember regulatory news can cause sharp price moves.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
